The present research revealed a significant decrease in the expression of the CBR1, CBR1a, and CBR2 in the placentas following PTB, in contrast to term births. These findings hold profound implications for clinical practice, indicating the potential for developing a new biomarker profile using CBR expression levels for PTB prediction. An innovative estimation technology has the potential to greatly transform prenatal care. It could help healthcare personnel detect high-risk pregnancies and take appropriate actions, ultimately improving neonatal outcomes.